Big Pharma Meets Big Data in a Big Way
Today, Boehringer Ingelheim’s, manufacturer of Pradaxa, new research partner, NextBio, announced that Boehringer Ingelheim is signing a multi-year renewal agreement with NextBio. NextBio provides data infrastructures for processing genomic data in hopes of providing useful insights into the causes of disease, which may lead to cures. The partnerships between NextBio and companies like Boehringer Ingelheim, GlaxoSmithKline, Pfizer, etc. are potentially a dangerous preview of the research that can be expected to come. “The technologies of the future may provide useful insights but they also expose patients to potential dangers of an unprecedented level. Companies like Boehringer Ingelheim and GlaxoSmithKline...
Read More